Sun, Dec 21, 2014, 4:31 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Venaxis, Inc. Message Board

  • peter_norths_proctologist peter_norths_proctologist Dec 9, 2007 3:56 AM Flag

    a link to the old Yahoo! message board

    I used to post on the old board, before they changed the symbol to APPY. Here is the link:

    http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/forumview?bn=30442

    I sold this stock way too soon, out of fear. Worst mistake I made in 2007. But I'm not a bio-tech investor. Congrats to those who held. Here is an old post of mine which makes reference to a US patent that was granted back in 1991, for an appendicitis *urine* test. That test appears to have been every bit as accurate as the APPY-score test.

    http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=mm&bn=30442&tid=48&mid=48&tof=14&rt=2&frt=1&off=1

    I still don't know why that urine test was never commercialized, when the medical community is supposedly dying for just such a test. It didn't add up in my head. But I am not an expert in this field by any means. And bio-tech stocks are definitely not my forte. I'd appreciate your comments on this . Thanks.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The patent application for the 1990's test appears to require 1) a chemical extraction 2) the use of a thin layer gas chromatograph (the average ER does not have this equipment nor does it have people trained to run this equipment) 3) the reading of a flourescent spot following the use of the chromatograph. ERs & docs may have been scared away by the equipment and personnel requirements.

    • Uroerythrin is the previous analyte tested. I suspect that the trial run by APPY is similar to the previous trial data. If Uroerythrin didn't make it, perhaps there is not enough demand for appendicitis testing.

      It could also be that whomever had the patent rights tried to sell the test to Abbott/JNJ/Roche..etc...and no one wanted to pay the royalties.

      APPY will have to be smart to get this test to market. They have no presence in the hospital market, so my guess is they will have to push the test through a partner. The stock price is definitely ahead of itself with all the question-marks. A good pump.

 
APPY
1.80+0.09(+5.26%)Dec 19 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Under Armour, Inc.
NYSEFri, Dec 19, 2014 4:04 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST
Auspex Pharmaceuticals, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST